Across TCGA pan-cancer cohorts, HLA-E Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HLA-E data layer compared with 27 for mass-spec protein and 9 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HLA-E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HLA-E expression acts as an unfavorable survival marker.

LUAD, GBM, and BLCA are the cancer types where HLA-E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →
GBM	OS	Median	All	0.024	0.416	<.001	12	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: HLA-E tumor-vs-normal RNA expression · all HLA-E data types